The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort

Journal of Translational Medicine

Flemming Brandt Sørensen²  Anders Jakobsen²  Jan Lindebjerg³  Thorarinn Blondal¹  Søren Morgenthaler¹  Sanne Kjær-Frifeldt³  Torben Frøstrup Hansen² 

[1] Diagnostic Product Development, Exiqon A/S, Vedbæk, Denmark;Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark;Department of Clinical Pathology, Vejle Hospital, part of Lillebaelt Hospital, Vejle, Denmark

关键词: Prognostic markers;    Microvessel density;    microRNA-126;    Duke¿s B;    Colon cancer;    Angiogenesis;   

Others  :  1148089
DOI  :  10.1186/s12967-014-0254-6

 received in 2014-06-16, accepted in 2014-09-03,  发布年份 2014

【 摘 要 】

Background

Angiogenesis plays a pivotal role in malignant tumour growth and the metastatic process. We analysed the prognostic value of two angiogenesis parameters, microRNA-126 (miRNA-126) and microvessel density (MVD), in a population based cohort of patients operated for stage II colon cancer.

Methods

A total of 560 patients were included. Analyses were performed on formalin fixed paraffin embedded tissue from the primary tumours. The analysis of miRNA-126 expression was performed by qPCR. Microvessels were visualised by CD105 and quantified in hot spots using a light microscope. The analyses were correlated with recurrence-free cancer specific survival (RF-CSS) and overall survival (OS).

Results

Low miRNA-126 expression was significantly correlated to T4, high malignancy grade, tumour perforation, fixation, and the presence of microsatellite instability. A prognostic impact on OS was detected in the simple analysis favouring patients with high miRNA-126 expression p?=?0.03, and borderline significance as to RF-CSS, p?=?0.08. The impact on OS demonstrated borderline significance in a following multiple Cox regression analysis, hazard ratio 0.76 (95% confidence interval, 0.58-1.00), p?=?0.051. The MVD estimate was not associated with either RF-CSS, p?=?0.49, or OS, p?=?0.94.

Conclusion

The current population based study of patients operated for stage II colon cancer demonstrated correlations between several prognostic unfavourable characteristics and miRNA-126 and argues for a possible prognostic impact on overall survival. An influence on survival by the MVD estimate was not detected.

【 授权许可】

   
2014 Hansen et al. licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321-326.
• [2]O¿Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246-250.
• [3]O¿Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA: Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011, 29:3381-3388.
• [4]Sargent D, Sobrero A, Grothey A, O¿Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O¿Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, De GA: Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009, 27:872-877.
• [5]Schmoll HJ, van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, et al.: ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012, 23:2479-2516.
• [6]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [7]Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4-6.
• [8]Des GG, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006, 94:1823-1832.
• [9]Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis¿correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
• [10]Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008, 9:102-114.
• [11]Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
• [12]Heusschen R, van Gink M, Griffioen AW, Thijssen VL: MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochim Biophys Acta 2010, 1805:87-96.
• [13]Bonauer A, Boon RA, Dimmeler S: Vascular microRNAs. Curr Drug Targets 2010, 11:943-949.
• [14]Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E, Horvitz HR, Kauppinen S, Plasterk RH: MicroRNA expression in zebrafish embryonic development. Science 2005, 309:310-311.
• [15]Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, Bai Y, Shen Y, Yuan W, Jing Q, Qin Y: Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem 2011, 351:157-164.
• [16]Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM, Busund LT: Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011, 117:3193-3200.
• [17]Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
• [18]Png KJ, Halberg N, Yoshida M, Tavazoie SF: A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011, 481:190-194.
• [19]Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, Yamamoto K, Kirita T, Kuniyasu H: Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 2012, 107:700-706.
• [20]Jusufovic E, Rijavec M, Keser D, Korosec P, Sodja E, Iljazovic E, Radojevic Z, Kosnik M: let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non--small--cell lung cancer.PLoS One 2012, doi:10.1371/journal.pone.0045577.
• [21]Diaz R, Silva J, Garcia JM, Lorenzo Y, Garcia V, Pena C, Rodriguez R, Munoz C, Garcia F, Bonilla F, Dominguez G: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008, 47:794-802.
• [22]Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, Kauppinen S, Orntoft TF, Andersen CL: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008, 68:6416-6424.
• [23]Hansen TF, Soerensen FB, Lindebjerg J, Jakobsen A: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.BMC Cancer 2012, doi:10.1186/1471-2407-12-83.
• [24]McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387-391.
• [25]Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J: Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol 2011, 119:92-101.
• [26]Kjaer-Frifeldt S, Hansen TF, Nielsen BS, Joergensen S, Lindebjerg J, Soerensen FB, Depont CR, Jakobsen A: The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer 2012, 107:1169-1174.
• [27]Hansen TF, Sorensen FB, Spindler KL, Olsen DA, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A: Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010, 456:251-260.
• [28]Gundersen HJ: Estimators of the number of objects per area unbiased by edge effects. Microsc Acta 1978, 81:07-117.
• [29]Carmeliet P, Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10:417-427.
• [30]Li XM, Wang AM, Zhang J, Yi H: Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol 2011, 28:1054-1057.
• [31]Hansen TF, Andersen CL, Nielsen BS, Spindler KL, Sorensen FB, Lindebjerg J, Brandslund I, Jakobsen A: Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncol Lett 2011, 2:1101-1106.
• [32]Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K: The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47:939-946.
• [33]Hansen TF, Nielsen BS, Jakobsen A, Sorensen FB: Visualising and quantifying angiogenesis in metastatic colorectal cancer: A comparison of methods and their predictive value for chemotherapy response. Cell Oncol 2013, 36:341-350.
• [34]Ebrahimi F, Gopalan V, Smith RA, Lam AK-Y: miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol 2014, 96:98-107.
• [35]Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008, 15:261-271.
• [36]van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, Van Zonneveld AJ: Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med 2009, 13:1577-1585.
• [37]Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N: MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 2010, 10:173. BioMed Central Full Text
• [38]Meyer SU, Pfaffl MW, Ulbrich SE: Normalization strategies for microRNA profiling experiments: a ¿normal¿ way to a hidden layer of complexity? Biotechnol Lett 2010, 32:1777-1788.
• [39]Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL: The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011, 104:1168-1177.
• [40]Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn¿t tell us. J Natl Cancer Inst 2002, 94:883-893.
• [41]Fonsatti E, Del VL, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M: Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001, 188:1-7.
• [42]Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
• [43]Elezoglu B, Tolunay S: The relationship between the stromal mast cell number, microvessel density, c-erbB-2 staining and survival and prognostic factors in colorectal carcinoma. Turk Patoloji Derg 2012, 28:110-118.
• [44]Gao J, Knutsen A, Arbman G, Carstensen J, Franlund B, Sun XF: Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis 2009, 41:116-122.